NCT03408665Active, not recruiting
Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
Intervention research involving the human person, phase II, prospective, multicentric, non-randomized and multi-cohort study. The eligibility criteria are broad, on purpose, so every patient, able to be treated by SBRT and unable to participate in another trial (non eligible patient or non included centers), can be included in this national study, in a prospective way.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 280 (actual)
- First submitted
- 4 Jan 2018
- Start date
- 13 Mar 2019
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Centre Oscar Lambret
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT03408665
What you commit to
- Study type: Interventional
- Participants enrolled: 280
- From 13 Mar 2019 to the primary completion date, 1 Dec 2026
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Eligibility to a curative surgery according to the multidisciplinary consultation meeting
Other
- Contraindication to SBRT (especially Cirrhose Child C)
- Pregnant or breastfeeding women
- Patient Under guardianship or tutorship
- Impossibility to submit at the study procedures due to geographic, social or mental reasons
Who the study is looking for
- Age ≥ 18 years old
- With primary or secondary liver tumor and matching one of the following situations:
- Liver Metastasis (LM): anatomopathologic diagnosis of the primary tumor
- Hepatocellular Carcinoma (HCC): diagnosis achieved through biopsy or through non-invasive methods approved by AASLD criteria (Bruix, 2011)
- Cholangiocarcinoma (CC): diagnosis achieved through biopsy
- Other primitive hepatic tumor achieved through biopsy
- Meet the requirements for SBRT treatment:
- Liver Metastasis (LM): oligometastatic disease
- Hepatocellular Carcinoma (HCC): non eligible lesion to curative surgery
- Cholangiocarcinoma (CC): nodular lesion
- Other primitive hepatic tumor: non eligible lesion to curative surgery
- Able to receive a SBRT treatment according to the multidisciplinary consultation meeting
- Tumor assessable with CT-scan or MRI according to mRECIST in HCC or Recist 1.1 in other situations
- Affiliation to the National Social Security System
- With informed and signed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Léonard de Vinci Coordinator of this site? Confirm its status | Dechy | France | Unknown status |
| Centre Oscar Lambret Coordinator of this site? Confirm its status | Lille | France | Unknown status |
| Institut Regional Du Cancer de Montpellier Coordinator of this site? Confirm its status | Montpellier | France | Unknown status |
| Institut De Cancerologie Paris Nord Coordinator of this site? Confirm its status | Sarcelles | France | Unknown status |
| Centre Paul Strauss Coordinator of this site? Confirm its status | Strasbourg | France | Unknown status |
| Institut de Cancérologie de Lorraine Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Unknown status |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.